सेफपोडोक्सिम के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें सेफपोडोक्सिम (Vantin; सेफालोस्पोरिन) के 79 इंटरैक्शन दर्ज हैं: 17 गंभीर, 31 मध्यम, 31 मामूली, और 0 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

सेफपोडोक्सिम दवा कैसी दिखती है

सभी 12 वेरिएंट
सेफपोडोक्सिम 100 mg टैबलेट: लाल, अंडाकार, 11 mm, विभाजन रेखा सहित, इम्प्रिंट F 3 1 00।
F / 3 / 1 / 00
100 mg · लाल · अंडाकार · 11 mm · विभाजन रेखा सहित
MWI/Vetone
सेफपोडोक्सिम 200 mg टैबलेट: नारंगी, अंडाकार, 16 mm, विभाजन रेखा सहित, इम्प्रिंट F 3 2 00।
F / 3 / 2 / 00
200 mg · नारंगी · अंडाकार · 16 mm · विभाजन रेखा सहित
MWI/Vetone
सेफपोडोक्सिम 100 mg टैबलेट: नारंगी, अंडाकार, 11 mm, विभाजन रेखा सहित, इम्प्रिंट 5228।
5228
100 mg · नारंगी · अंडाकार · 11 mm · विभाजन रेखा सहित
Zoetis
सेफपोडोक्सिम 200 mg टैबलेट: नारंगी, अंडाकार, 15 mm, विभाजन रेखा सहित, इम्प्रिंट 5228।
5228
200 mg · नारंगी · अंडाकार · 15 mm · विभाजन रेखा सहित
Zoetis

FDA लेबल की प्रोडक्ट लिस्टिंग से बनाई गई रेंडरिंग: रंग, आकार, साइज़ और इम्प्रिंट। 11 लेबलर के 12 दर्ज वेरिएंट।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (17)

  • इमिपेनेम और सिलास्टैटिनएंटीबायोटिकगंभीर

    Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (इमिपेनेम और सिलास्टैटिन लेबल, चेतावनियां और सावधानियां)

  • एमोक्सिसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    AMOXIL is contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AMOXIL or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (एमोक्सिसिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एमोक्सिसिलिन और क्लैवुलैनेटपेनिसिलिन एंटीबायोटिकगंभीर

    History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AUGMENTIN or to other beta‑lactams (e.g., penicillins or cephalosporins). (एमोक्सिसिलिन और क्लैवुलैनेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एम्पीसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    CONTRAINDICATIONS The use of Ampicillin is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin or to other beta-lactam antibacterial drugs. (एम्पीसिलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एम्पीसिलिन और सल्बैक्टमपेनिसिलिन एंटीबायोटिकगंभीर

    CONTRAINDICATIONS The use of UNASYN is contraindicated in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to ampicillin, sulbactam or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins). (एम्पीसिलिन और सल्बैक्टम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एर्टापेनेमएंटीबायोटिकगंभीर

    INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (एर्टापेनेम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • नैफसिलिनपेनिसिलिन एंटीबायोटिकगंभीर

    WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. (नैफसिलिन लेबल, चेतावनियां)

  • पाइपेरासिलिन और टैज़ोबैक्टमपेनिसिलिन एंटीबायोटिकगंभीर

    Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or betalactamase inhibitors. (पाइपेरासिलिन और टैज़ोबैक्टम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफाक्लोरसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Cefaclor extended-release tablets are contraindicated in patients with known hypersensitivity to cefaclor and other cephalosporins. (सेफाक्लोर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफाज़ोलिनसेफालोस्पोरिनगंभीर

    Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (सेफाज़ोलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफिक्सिमसेफालोस्पोरिनगंभीर

    Contraindicated in patients with known allergy to cefixime or other cephalosporins. (सेफिक्सिम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफेपिमसेफालोस्पोरिनगंभीर

    Patients with known immediate hypersensitivity reactions to cefepime or other cephalosporins, penicillins or other beta-lactam antibacterial drugs. (सेफेपिम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफैलेक्सिनसेफालोस्पोरिनगंभीर

    Cephalexin is contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. (सेफैलेक्सिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफॉक्सिटिनसेफालोस्पोरिनगंभीर

    Hypersensitivity to cefoxitin or other beta-lactam antibacterial drugs. (सेफॉक्सिटिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्टारोलिनसेफालोस्पोरिनगंभीर

    CONTRAINDICATIONS Teflaro is contraindicated in patients with known serious hypersensitivity to ceftaroline or other members of the cephalosporin class. (सेफ्टारोलिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्ट्रिएक्सोनसेफालोस्पोरिनगंभीर

    Anaphylaxis to ceftriaxone or other cephalosporin class antibacterials, penicillins, or other beta-lactam antibacterials ( 4.1 ) (सेफ्ट्रिएक्सोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • सेफ्यूरोक्सिमसेफालोस्पोरिनगंभीर

    Known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other β-lactams (e.g., penicillins and cephalosporins). (सेफ्यूरोक्सिम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

मध्यम इंटरैक्शन (31)

  • Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • एंटासिड (Tums, Maalox, Mylanta)बिना पर्चे की दवा (OTC)मध्यम

    Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • एज़ट्रियोनमएंटीबायोटिकमध्यम

    Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (एज़ट्रियोनम लेबल, चेतावनियां और सावधानियां)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकमध्यम

    Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (एथाक्रिनिक एसिड लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सासिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • ओमेप्राज़ोल और सोडियम बाइकार्बोनेटप्रोटॉन पंप इनहिबिटरमध्यम

    Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • जेंटामाइसिनएमिनोग्लाइकोसाइडमध्यम

    Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. (जेंटामाइसिन लेबल, दवाओं के इंटरैक्शन)

  • डाइक्लोक्सासिलिनपेनिसिलिन एंटीबायोटिकमध्यम

    IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • निज़ाटिडीनH2 ब्लॉकरमध्यम

    Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • पाइरिडोस्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरमध्यम

    Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • पाइलोकार्पिनकोलिनर्जिक एगोनिस्टमध्यम

    Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • पेनिसिलिन Gपेनिसिलिन एंटीबायोटिकमध्यम

    IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • पेनिसिलिन Vपेनिसिलिन एंटीबायोटिकमध्यम

    IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (प्रोटामिन लेबल, सावधानियां)

  • Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • फैमोटिडीनH2 ब्लॉकरमध्यम

    Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकमध्यम

    Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. (फ्यूरोसेमाइड लेबल, दवाओं के इंटरैक्शन)

  • बेथानेकोलकोलिनर्जिक एगोनिस्टमध्यम

    Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • माइकोफेनोलेटइम्यूनोसप्रेसेंटमध्यम

    Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (माइकोफेनोलेट लेबल, दवाओं के इंटरैक्शन)

  • रैनिटिडीनH2 ब्लॉकरमध्यम

    Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सिमेटिडीनH2 ब्लॉकरमध्यम

    Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेफडिनिरसेफालोस्पोरिनमध्यम

    Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेफप्रोज़िलसेफालोस्पोरिनमध्यम

    Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेफाड्रोक्सिलसेफालोस्पोरिनमध्यम

    Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेफोटेटनसेफालोस्पोरिनमध्यम

    Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेफोटैक्सिमसेफालोस्पोरिनमध्यम

    Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेफ्टाज़िडिमसेफालोस्पोरिनमध्यम

    Probenecid As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • सेविमेलिनकोलिनर्जिक एगोनिस्टमध्यम

    Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • Drug Interactions Antacids Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H 2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

  • स्कोपोलामाइन (हायोसिन)एंटीकोलिनर्जिकमध्यम

    Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). (सेफपोडोक्सिम लेबल, दवाओं के इंटरैक्शन)

मामूली ज़िक्र (31)

  • आर्टिकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • एज़ेलास्टिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • एज़ेलास्टिन और फ्लुटिकासोनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • एड्रेनालिनसिम्पैथोमिमेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • ओलोपाटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • ओलोपाटाडीन और मोमेटासोनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • कार्बिनोक्सामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • क्लेमास्टिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • क्लोरफेनिरामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • डाइफेनहाइड्रामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • डाइमेनहाइड्रिनेटएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • डेक्सक्लोरफेनिरामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • डेसलोराटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • डॉक्सीलामिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • डॉक्सीलामिन और पाइरिडोक्सिनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • प्रिलोकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • प्रोमेथाज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • फेक्सोफेनाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • ब्यूपिवाकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • मेक्लिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • मेरोपेनेमएंटीबायोटिकमामूली

    Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (मेरोपेनेम लेबल, चेतावनियां और सावधानियां)

  • लिडोकेन और एड्रेनालिनलोकल एनेस्थेटिकमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • लेवोसेटिरिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • लोराटाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • साइप्रोहेप्टाडीनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • सेटिरिज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • हाइड्रॉक्सीज़िनएंटीहिस्टामिनमामूली

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

  • SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (सेफपोडोक्सिम लेबल, चेतावनियां)

आप जो कुछ भी लेते हैं, उस सबके साथ सेफपोडोक्सिम को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।